Table 3

Association between FMO3 genotypes and clinical outcome in patients treated with sulindac

PolymorphismsPolyps (nonresponders) n = 9No polyps (responders) n = 12
P153L
WT/WT8 (89)11 (92)
WT/P1 (11)1 (8)
P/P00
E158K
WT/WT4 (44)3 (25)
WT/P5 (56)5 (42)
P/P04 (33)
V257M
WT/WT9 (100)10 (83)
WT/P02 (17)
P/P00
E305X
WT/WT6 (67)8 (67)
WT/P3 (33)4 (33)
P/P00
E308G
WT/WT2 (22)0
WT/P7 (78)10 (83)
P/P02 (17)
  • NOTE. Values are expressed as number (%).